Free tool
Drug Trial Radar: Pain and anesthesia
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
13
Not yet recruiting, industry sponsors, Pain and anesthesia, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed965
13 trials
Showing 1 to 13, recently updated first.
- A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic SurgeryPivotal-lookingNot yet recruiting
AFT Pharmaceuticals, Ltd.Industry
NCT07225140 · 180 participants (planned) · Start Jan 2027 · Primary completion Oct 2027
Drug: Combogesic® tablets; Acetaminophen 500mg and 1 more · For: Post Operative Pain, Acute
Sites: Orlando, Florida
- Phase 3 Bunionectomy StudyPivotal-lookingNot yet recruiting
Cali Pharmaceuticals LLCIndustry
NCT07490496 · 112 participants (planned) · Start Mar 1, 2027 · Primary completion Jun 30, 2027
Drug: CPL-01; saline placebo · For: Postoperative Pain; Bunion
Sites: Salt Lake City, Utah
- Efficacy and Safety of DNN.63.18.040 for the Treatment of Moderate to Severe PainPivotal-lookingNot yet recruiting
Ache Laboratorios Farmaceuticos S.A.Industry
NCT07880392 · 370 participants (planned) · Start Oct 19, 2026 · Primary completion Mar 2027
Drug: Product DNN.63.18.040; Tramal® · For: Acute Pain
- A Study to Evaluate Efficacy and Safety of a Single Intra-Articular Injection of HL-01 in the Treatment of Pain in Symptomatic Knee OsteoarthritisPivotal-lookingNot yet recruiting
IBSA Institut Biochimique SAIndustry
NCT07819461 · 704 participants (planned) · Start Sep 30, 2026 · Primary completion Jun 30, 2027
Drug: Sodium hyaluronate solution - 3.36%; Sterile buffered solution · For: Osteo Arthritis of the Knee
- Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).Pivotal-lookingNot yet recruiting
Okyo Pharma LtdIndustry
NCT07838506 · 111 participants (planned) · Start Sep 2026 · Primary completion May 2027
Drug: Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks. · For: Neuropathic Corneal Pain
Sites: Nashville, Tennessee
- Efficacy and Safety of GNSC-001 Intra-articular Injection for Knee OsteoarthritisPivotal-lookingNot yet recruiting
Genascence CorporationIndustry
NCT07831577 · 240 participants (planned) · Start Jul 2027 · Primary completion Oct 2029
Drug: Gene Therapy GNSC-001; Placebo · For: Knee Arthritis Osteoarthritis; Knee Arthritis, Osteoarthritis; Knee Arthritis and 6 more
- Corticosteroid Lumbar Epidural Analgesia for Radicular Pain 2Pivotal-lookingNot yet recruiting
Semnur Pharmaceuticals, Inc.Industry
NCT07579351 · 755 participants (planned) · Start Feb 2027 · Primary completion Nov 2028
Drug: SP-102; Placebo and 1 more · For: Lumbosacral Radicular Pain
- HSK3486 (Cipepofol) Injectable Emulsion for Induction of General Anesthesia in Pediatric Subjects Undergoing Elective SurgeryPivotal-lookingNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07510945 · 400 participants (planned) · Start May 2026 · Primary completion May 2028
Drug: HSK3486; propofol · For: General Anesthetic
- Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal InjectionsPivotal-lookingNot yet recruiting
iRenix Medical, Inc.Industry
NCT05750589 · 240 participants (planned) · Start Sep 1, 2026 · Primary completion Jan 31, 2027
Drug: IRX-101; Providone-Iodine · For: Retinal Disease
Sites: San Antonio, Texas
- A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive CrisisPivotal-lookingNot yet recruiting
Asklepion Pharmaceuticals, LLCIndustry
NCT06989567 · 120 participants (planned) · Start Jul 25, 2025 · Primary completion Jun 2027
Drug: L-citrulline · For: Sickle Cell Disease
Sites: Washington D.C., District of Columbia; Coral Gables, Florida; Atlanta, Georgia · 6 sites in all
- Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in ChinaPivotal-lookingNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06422117 · 408 participants (planned) · Start May 30, 2024 · Primary completion Jul 30, 2027
Drug: HSK16149 20mg-40mg BID; Placebo · For: Central Neuropathic Pain
- Efficacy and Safety of DEH113 in the Treatment of Menstrual Cramp Pain Associated With Primary DysmenorrheaPivotal-lookingNot yet recruiting
EMSIndustry
NCT06268054 · 78 participants (planned) · Start Feb 2025 · Primary completion Feb 2027
Drug: DEH113; Placebo Comparator · For: Primary Dysmenorrhea
- Efficacy and Safety of DIT112 in the Treatment of Moderate to Severe Pain After Dental Surgery for the Extraction of Impacted Third MolarsPivotal-lookingNot yet recruiting
EMSIndustry
NCT06237231 · 252 participants (planned) · Start Feb 15, 2025 · Primary completion Mar 15, 2025
Drug: DIT112; DIPYRONE and 4 more · For: Moderate Pain; Severe Pain
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.